TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability

Sha Zhou(Sun Yat-sen University), Zhenlin Hou(Sun Yat-sen University)
Cell Death and Disease
May 8, 2021
10.1038/s41419-021-03734-4
Cited by 65

Related Papers

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer
|Autophagy|2023|387
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
|Research Square|2020|2
TRIM25 Regulates Oxaliplatin Resistance in Colorectal Cancer by Promoting EZH2 Stability
|Research Square|2020|2